Format

Send to

Choose Destination
BMJ Case Rep. 2016 Apr 29;2016. pii: bcr2016215797. doi: 10.1136/bcr-2016-215797.

Persistent bone marrow depression following short-term treatment with temozolomide.

Author information

1
Oslo University Hospital, Oslo, Norway.
2
Department of Hematology, Oslo University Hospital, Oslo, Norway.

Abstract

Temozolomide (TMZ) is, in combination with radiotherapy (RT), the treatment of choice for glioblastoma multiforme. Although generally well tolerated, haematological side effects are observed in approximately 1-10% of patients receiving TMZ. We report a case of a patient who developed severe bone marrow failure (BMF) after only 3 weeks of concomitant TMZ. The BMF was grave with no signs of improvement for 12 months, resulting in more than 100 transfusions of blood cells.

PMID:
27130558
PMCID:
PMC4854153
DOI:
10.1136/bcr-2016-215797
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central Icon for Norwegian BIBSYS system
Loading ...
Support Center